Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.52 |
| ▸ | MTOR | P42345 | 3/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 13/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 13/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | EIF4E | P06730 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18584581 | 0.88 | MKNK1 (0.57) | PIK3CAMTORMKNK1MKNK2CYP3A4 | |
| SCHEMBL15285823 | 0.86 | MKNK1 (0.50) | MKNK1MKNK2CYP3A4EIF4EFYN | |
| SCHEMBL18609148 | 0.86 | PIK3CA (0.58) | PIK3CAMTORMKNK1MKNK2CYP3A4 | |
| SCHEMBL15288077 | 0.83 | MKNK1 (0.68) | PIK3CAMKNK1MKNK2CYP3A4EIF4E | |
| SCHEMBL3847512 | 0.82 | MKNK1 (0.51) | PIK3CAMTORMKNK1MKNK2CYP3A4 | |
| SCHEMBL18609374 | 0.81 | CHEK1 (0.55) | MKNK1MKNK2CHEK1CYP3A4EIF4E | |
| SCHEMBL19781183 | 0.80 | KMT2A (0.54) | MKNK1MKNK2CYP3A4EIF4EFYN | |
| SCHEMBL18609186 | 0.77 | KCNH2 (0.70) | PIK3CAMTORCHEK1GSK3BCYP3A4 | |
| SCHEMBL15288165 | 0.77 | EPHB3 (0.44) | MKNK1MKNK2CYP3A4EIF4EFYN | |
| SCHEMBL28484621 | 0.77 | MKNK1 (0.42) | MKNK1MKNK2CYP3A4EIF4EFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730842-B2 | Small molecule inhibitors of DYRK1A and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730842-B2 | Small molecule inhibitors of DYRK1A and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-08-04 | — | — | US | disclosed |
| WO-2017040993-A1 | SMALL MOLECULE INHIBITORS OF DYRK1A AND USES THEREOF | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730842-B2 | Small molecule inhibitors of DYRK1A and uses thereof | DYRK1A, DYRK2, DYRK1B | PIK3CA 2508/4885MTOR 1341/4885MKNK1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.